1.	Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX1401-01, NCT00948961
2.	Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.26, NCT00748709
3.	A Phase I Study of Alemtuzumab Delivered Intraperitoneally in Patients With Relapsed Ovarian Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.120, NCT00637390
4.	A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 Given on a Daily Oral Regimen in Subjects With Advanced Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ARRAY-380-101, NCT00650572
5.	A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX-1307-01, NCT00709462
6.	MK4827 in Patients With Advanced Solid Tumors and BRCA Mutant Ovarian Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2008_501, NCT00749502
7.	Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL147-003, NCT00756847
8.	Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: HBS601, NCT00765973
9.	Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MI-CP177, NCT00796055
10.	Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ATDTRPST0802, NCT00800345
11.	Randomized, Double Blind, Placebo-Controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 05-409, NCT00821652
12.	Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TAMC 3H04, NCT00160472
13.	Pilot Study of MDR modulator CBT-1 and Paclitaxel in Patients With Refractory, Recurrent, or Advanced Metastatic Solid Tumors Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-08-C-0035, 08-C-0035, NCT00658424
14.	The Effect of TRA-8 on Ovarian Cancer Tissue Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: F080328006/UAB0802, ROI CA 123197-01, NCT00711932
15.	Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy Phase: No phase specified Type: Health services research, Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: 08-092, NCT00746018